Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 1.00 |
| ▸ | TFEB | P19484 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | BACE1 | P56817 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.60 |
| ▸ | AR | P10275 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598851 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL7414400 | 0.94 | NFE2L2 (0.88) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL10667607 | 0.94 | NFE2L2 (0.88) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL10667601 | 0.94 | NFE2L2 (0.88) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL7414394 | 0.94 | NFE2L2 (0.88) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL2623834 | 0.90 | NFE2L2 (0.81) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL17691543 | 0.89 | NFE2L2 (0.80) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL10756384 | 0.88 | NFE2L2 (0.78) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| SCHEMBL3198204 | 0.88 | BACE1 (0.81) | NFE2L2MAPTBACE1APPMAOB | |
| SCHEMBL3198218 | 0.88 | BACE1 (0.81) | NFE2L2MAPTBACE1APPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | IONS PHARMACEUTICAL S.À R.L. (LU) | 2016-04-21 | — | — | US | disclosed |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150087705-A1 | Protective Effects of Curcumin Against Hemorrhagic Stroke Injury | AUGUSTA UNIVERSITY | 2015-03-26 | — | — | US | disclosed |
| US-20150087705-A1 | Protective Effects of Curcumin Against Hemorrhagic Stroke Injury | AUGUSTA UNIVERSITY | 2015-03-26 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | NFE2L2 1139/4885TFEB 705/4885KDM4E 1842/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885KDM4E 3658/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885KDM4E 3658/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885KDM4E 3658/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | NFE2L2 1139/4885TFEB 705/4885KDM4E 1842/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
| US-20150087705-A1 | Protective Effects of Curcumin Against Hemorrhagic Stroke Injury | NFKBIA, AP1G1, NFRKB | NFE2L2 14/4885TFEB 59/4885KDM4E 2411/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | NFE2L2 1139/4885TFEB 705/4885KDM4E 1842/4885 |
| US-20160106724-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | NFE2L2 5/4885TFEB 346/4885KDM4E 2055/4885 |
| US-20160106687-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885KDM4E 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.